Natera, Inc.'s (NASDAQ:NTRA) CEO and President, Steven Leonard Chapman, recently sold 4,084 shares of the company's common stock on April 29, according to the latest SEC filing. The sale was executed at an average price of $93.14 per share, totaling approximately $380,378.
The transaction was part of a prearranged 10b5-1 trading plan, which allows company insiders to set up a predetermined plan to sell stocks at a time when they are not in possession of material non-public information. This plan is often used to avoid any potential conflicts of interest or accusations of insider trading.
Following the sale, Chapman still owns a substantial number of shares in Natera, with 226,235 shares remaining in his possession. The sale was made public through an SEC Form 4 filing, which insiders must file to report transactions in their company's stock.
Investors often keep an eye on insider transactions as they can provide insights into an insider’s view of the company's future prospects. However, it's important to note that these transactions can be subject to various factors, including personal financial planning and diversification strategies.
Natera is a leader in the field of genetic testing and diagnostics, providing a range of services including prenatal testing, cancer screening, and organ health monitoring. The company's stock is publicly traded on the NASDAQ exchange, where investors can follow its performance under the ticker symbol NTRA.
InvestingPro Insights
As Natera, Inc. (NASDAQ:NTRA) navigates the market following insider transactions, investors may find the current InvestingPro data and tips to be of particular interest. With a market capitalization of $11.46 billion, the company showcases significant size in the genetic testing industry. Despite a negative P/E ratio of -24.80, reflecting its current lack of profitability, the company has experienced substantial revenue growth in the last twelve months as of Q4 2023, with an increase of 31.99%. This growth is further accentuated in the most recent quarter of Q4 2023, where revenue growth reached an impressive 43.2%.
InvestingPro Tips highlight that Natera has not been profitable over the last twelve months, and analysts do not expect the company to be profitable this year. However, the company's liquid assets surpass its short-term obligations, which could suggest financial stability in meeting its immediate financial commitments. Moreover, Natera is trading near its 52-week high, with the price at 94.84% of this peak, indicating strong market confidence in the stock.
For those considering an investment in Natera, it's worth noting that the company has delivered a strong return over the last three months, with a price total return of 39.01%. Additionally, there are 11 more InvestingPro Tips available for Natera, which could provide further insights into the company's financial health and stock performance. Interested investors can use coupon code PRONEWS24 to get an additional 10% off a yearly or biyearly Pro and Pro+ subscription to access these valuable tips.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.